Our work indicates that a variety of deleterious CHEK2 alleles make an appreciable contribution to breast cancer susceptibility, and their identification could help in the clinical management of patients carrying a CHEK2 mutation.
No takes yet. Share an insight, caveat, or question.
Desrichard et al. (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: